Loading
A phase 3 trial testing Chiauranib in ovarian cancer, now recruiting.
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer is a phase 3 interventional study registered as NCT04921527, led by Chipscreen Biosciences, and recruiting on the registry. Official title: A Multi-centre, Double-blind, Randomised Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer. Planned enrolment is 454 participants (estimated). The study started in 2021-12-20 and primary completion is expected in 2024-12-31. No results have been posted on ClinicalTrials.gov.